IP Library Granted Patent US 11,235,049
Granted Patent B2
US 11,235,049 · App. 15/774,168 · Granted Feb 1, 2022

Polypeptides of fusobacterium and methods of use

Inventors: Charles Nelson Carver, III (Spicer, MN); Daryll A. Emery (New London, MN)
Assignee: Epitopix, LLC
A61K39/114A61K39/39A61P31/04C07K14/195G01N33/56911C12N2500/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,235,049
App. No.
15/774,168
Granted
Feb 1, 2022
Kind
B2
Abstract

The present invention provides isolated polypeptides isolatable from a Fusobacterium spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.

Claims (26)

1. A composition comprising:

an isolated polypeptide having a molecular weight of 131 kDa to 121 kDa, an isolated polypeptide having a molecular weight of 79 kDa to 69 kDa, and an isolated polypeptide having a molecular weight of 33 kDa to 23 kDa, wherein the polypeptides are isolated from a Fusobacterium necrophorum subsp. necrophorum , wherein the polypeptides are expressed when incubated in media comprising a copper chelator and not expressed at a detectable level when grown in the media without the copper chelator, wherein the copper chelator is quercetin added to the media at a concentration of 50 mM, and wherein molecular weight is as determined by 10% SDS-PAGE under reducing and denaturing conditions, and

an isolated polypeptide having a molecular weight of 93 kDa to 83 kDa and an isolated polypeptide having a molecular weight of 52 kDa to 42 kDa, wherein the polypeptides are isolated from the Fusobacterium necrophorum subsp. necrophorum when incubated in media comprising a copper chelator, wherein the polypeptides are expressed by the Fusobacterium necrophorum subsp. necrophorum when incubated in media without the copper chelator and are expressed at an enhanced level during growth in media comprising the copper chelator, wherein the copper chelator is quercetin added to the media at a concentration of 50 mM, and wherein molecular weight is as determined by 10% SDS-PAGE under reducing and denaturing conditions, and

a pharmaceutically acceptable adjuvant.

2. The composition of claim 1 further comprising:

a polypeptide having at least 85% similarity to amino acids 63-714 of SEQ ID NO:4, a polypeptide having at least 85% similarity to amino acids 63-736 of SEQ ID NO:6, a polypeptide having at least 85% similarity to amino acids 63 to 638 of SEQ ID NO:34, a polypeptide having at least 85% similarity to amino acids 63-1420 of SEQ ID NO:53, or a combination thereof.

3. A method comprising:

administering to a subject an amount of the composition of claim 1 effective to induce the subject to produce antibody that specifically binds to at least one polypeptide of the composition.

4. A method for treating an infection in a subject, the method comprising:

administering an effective amount of the composition of claim 1 to a subject having or at risk of having an infection caused by a Fusobacterium spp.

5. A method for treating a symptom in a subject, the method comprising:

administering an effective amount of the composition of claim 1 to a subject having or at risk of having an infection caused by a Fusobacterium spp.

6. A method for decreasing colonization in a subject, the method comprising:

administering an effective amount of the composition of claim 1 to a subject colonized by or at risk of being colonized by a Fusobacterium spp.

7. The method of claim 3 wherein the subject is a mammal.

8. The method of claim 7 wherein the mammal is a human, a bovine, or an ovine.

9. The method of claim 4 wherein the Fusobacterium spp. is F. necrophorum.

10. The method of claim 3 wherein at least 10 micrograms (μg) and no greater than 2000 μg of polypeptide is administered.

11. The method of claim 4 wherein the infection causes a condition selected from metritis, hepatic abscesses, and foot rot.

12. A kit for detecting antibody that specifically binds a polypeptide, comprising in separate containers:

the composition of claim 1 ; and

a reagent that detects an antibody that specifically binds to a polypeptide of the composition.

13. The composition of claim 1 further comprising:

a polypeptide comprising an amino acid sequence having at least 85% similarity to amino acids 63-714 of SEQ ID NO:4, a polypeptide comprising an amino acid sequence having at least 85% similarity to amino acids 63-736 of SEQ ID NO:6, a polypeptide comprising an amino acid sequence having at least 85% similarity to amino acids 63 to 638 of SEQ ID NO:34, a polypeptide having comprising an amino acid sequence at least 85% similarity to amino acids 63-1420 of SEQ ID NO:53, or a combination thereof.

14. The composition of claim 1 , wherein the three isolated polypeptides that are expressed when incubated in media comprising a copper chelator and not expressed at a detectable level when grown in the media without the copper chelator have molecular weights of 126 kDa, 74 kDa, and 28 kDa, and wherein the two polypeptides that are expressed by the Fusobacterium necrophorum subsp. necrophorum when incubated in media without the copper chelator and expressed at an enhanced level during growth in media comprising the copper chelator have molecular weights of 88 kDa, and 48 kDa.

15. The composition of claim 1 , wherein the polypeptide having a molecular weight of 52 kDa to 42 kDa has at least 85% similarity to amino acids 63-423 of SEQ ID NO:2.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2024
From: EPITOPIX, LLC
To: VAXXINOVA US, INC.
Reel/Frame 066488/0734 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 24, 2018
From: CARVER III, CHARLES NELSON; EMERY, DARYLL A.
To: EPITOPIX, LLC
Reel/Frame 046442/0229 →
Continuity (2)
Provisional Application 62252951 · Nov 9, 2015
Related Publication 20190224297A1 · Jul 25, 2019